Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Catheter Precision ( (VTAK) ) just unveiled an update.
On February 12, 2026, Catheter Precision, Inc. entered into Series J Exchange Agreements with CEO David A. Jenkins and his affiliated entity FatBoy Capital, LP, converting royalty rights and accrued royalty amounts with a net present value of about $9.49 million as of December 31, 2025 into 9,489.488 shares of newly created Series J Convertible Preferred Stock. Those preferred shares, issued under a certificate of designation filed in Delaware on February 9 and corrected on February 12, 2026, are convertible into approximately 6.08 million common shares at a fixed price of $1.56 per share, contingent on shareholder approval under NYSE American rules, and the exchange terminates the underlying royalty obligations as of year-end 2025.
On the same date, the company announced that it had secured up to $36.5 million in strategic institutional financing, while agreeing to terminate its at-the-market equity offering program and indicating it does not anticipate future equity lines of credit or forward-priced agreements. Together with converting roughly $9 million of additional liabilities into equity and extending short-term notes to two- and three-year maturities, the transactions are intended to materially strengthen Catheter Precision’s balance sheet, enhance liquidity, and align long-term institutional capital to fund growth initiatives and support expanded market execution.
The most recent analyst rating on (VTAK) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Catheter Precision stock, see the VTAK Stock Forecast page.
Spark’s Take on VTAK Stock
According to Spark, TipRanks’ AI Analyst, VTAK is a Neutral.
The score is primarily weighed down by weak financial performance driven by very large ongoing losses and significant cash burn, despite improving revenue. Technicals add additional pressure as the stock trades below major moving averages with negative MACD. Valuation contributes limited support because losses make P/E less informative and no dividend yield is available.
To see Spark’s full report on VTAK stock, click here.
More about Catheter Precision
Catheter Precision, Inc. is a U.S.-based medical device company focused on advanced electrophysiology solutions for the treatment of cardiac arrhythmias. The company develops and commercializes innovative technologies in collaboration with physicians, aiming to expand its market presence in cardiac care through continued product innovation.
Average Trading Volume: 37,606
Technical Sentiment Signal: Strong Sell
Current Market Cap: $3.25M
Find detailed analytics on VTAK stock on TipRanks’ Stock Analysis page.